Eric S Hall1, Scott L Wexelblatt2, Moira Crowley3, Jennifer L Grow4, Lisa R Jasin5, Mark A Klebanoff6, Richard E McClead7, Jareen Meinzen-Derr8, Vedagiri K Mohan9, Howard Stein9, Michele C Walsh3. 1. Perinatal Institute, Cincinnati Children's Hospital, Cincinnati, Ohio; eric.hall@cchmc.org. 2. Perinatal Institute, Cincinnati Children's Hospital, Cincinnati, Ohio; 3. Department of Pediatrics, University Hospitals Rainbow Babies and Children's Hospital and Case Western Reserve University, Cleveland, Ohio; 4. Department of Neonatology, Akron Children's Hospital, Akron, Ohio; 5. Department of Nursing, Dayton Children's Hospital, Dayton, Ohio; 6. The Research Institute, and. 7. Department of Neonatology, Nationwide Children's Hospital, Columbus, Ohio; 8. Perinatal Institute, Cincinnati Children's Hospital, Cincinnati, Ohio;Department of Biostatistics and Epidemiology, Cincinnati Children's Hospital, Cincinnati, Ohio; and. 9. Department of Neonatology, ProMedica Toledo Children's Hospital, Toledo, Ohio.
Abstract
OBJECTIVES: To compare pharmacologic treatment strategies for neonatal abstinence syndrome (NAS) with respect to total duration of opioid treatment and length of inpatient hospital stay. METHODS: We conducted a cohort analysis of late preterm and term neonates who received inpatient pharmacologic treatment of NAS at one of 20 hospitals throughout 6 Ohio regions from January 2012 through July 2013. Physicians managed NAS using 1 of 6 regionally based strategies. RESULTS: Among 547 pharmacologically treated infants, we documented 417 infants managed using an established NAS weaning protocol and 130 patients managed without protocol-driven weaning. Regardless of the treatment opioid chosen, when we accounted for hospital variation, infants receiving protocol-based weans experienced a significantly shorter duration of opioid treatment (17.7 vs. 32.1 days, P < .0001) and shorter hospital stay (22.7 vs. 32.1 days, P = .004). Among infants receiving protocol-based weaning, there was no difference in the duration of opioid treatment or length of stay when we compared those treated with morphine with those treated with methadone. Additionally, infants treated with phenobarbital were treated with the drug for a longer duration among those following a morphine-based compared with methadone-based weaning protocol. (P ≤ .002). CONCLUSIONS: Use of a stringent protocol to treat NAS, regardless of the initial opioid chosen, reduces the duration of opioid exposure and length of hospital stay. Because the major driver of cost is length of hospitalization, the implications for a reduction in cost of care for NAS management could be substantial.
OBJECTIVES: To compare pharmacologic treatment strategies for neonatal abstinence syndrome (NAS) with respect to total duration of opioid treatment and length of inpatient hospital stay. METHODS: We conducted a cohort analysis of late preterm and term neonates who received inpatient pharmacologic treatment of NAS at one of 20 hospitals throughout 6 Ohio regions from January 2012 through July 2013. Physicians managed NAS using 1 of 6 regionally based strategies. RESULTS: Among 547 pharmacologically treated infants, we documented 417 infants managed using an established NAS weaning protocol and 130 patients managed without protocol-driven weaning. Regardless of the treatment opioid chosen, when we accounted for hospital variation, infants receiving protocol-based weans experienced a significantly shorter duration of opioid treatment (17.7 vs. 32.1 days, P < .0001) and shorter hospital stay (22.7 vs. 32.1 days, P = .004). Among infants receiving protocol-based weaning, there was no difference in the duration of opioid treatment or length of stay when we compared those treated with morphine with those treated with methadone. Additionally, infants treated with phenobarbital were treated with the drug for a longer duration among those following a morphine-based compared with methadone-based weaning protocol. (P ≤ .002). CONCLUSIONS: Use of a stringent protocol to treat NAS, regardless of the initial opioid chosen, reduces the duration of opioid exposure and length of hospital stay. Because the major driver of cost is length of hospitalization, the implications for a reduction in cost of care for NAS management could be substantial.
Authors: Jodi S Dashe; Jeanne S Sheffield; Debora A Olscher; Sally J Todd; Gregory L Jackson; George D Wendel Journal: Obstet Gynecol Date: 2002-12 Impact factor: 7.661
Authors: Michael T Bigham; Rick Amato; Pattie Bondurrant; Jon Fridriksson; Catherine D Krawczeski; Jenni Raake; Sue Ryckman; Steve Schwartz; Julie Shaw; Dan Wells; Richard J Brilli Journal: J Pediatr Date: 2008-12-03 Impact factor: 4.406
Authors: J D Horbar; J Rogowski; P E Plsek; P Delmore; W H Edwards; J Hocker; A D Kantak; P Lewallen; W Lewis; E Lewit; C J McCarroll; D Mujsce; N R Payne; P Shiono; R F Soll; K Leahy; J H Carpenter Journal: Pediatrics Date: 2001-01 Impact factor: 7.124
Authors: Stephen W Patrick; Robert E Schumacher; Brian D Benneyworth; Elizabeth E Krans; Jennifer M McAllister; Matthew M Davis Journal: JAMA Date: 2012-04-30 Impact factor: 56.272
Authors: Brian T Bateman; Sonia Hernandez-Diaz; James P Rathmell; John D Seeger; Michael Doherty; Michael A Fischer; Krista F Huybrechts Journal: Anesthesiology Date: 2014-05 Impact factor: 7.892
Authors: Stephen W Patrick; Robert E Schumacher; Jeffrey D Horbar; Madge E Buus-Frank; Erika M Edwards; Kate A Morrow; Karla R Ferrelli; Alan P Picarillo; Munish Gupta; Roger F Soll Journal: Pediatrics Date: 2016-04-15 Impact factor: 7.124
Authors: Zana Percy; Cole Brokamp; Jennifer M McAllister; Patrick Ryan; Scott L Wexelblatt; Eric S Hall Journal: J Pediatr Date: 2020-05-15 Impact factor: 4.406
Authors: Tyler N A Winkelman; Nicole Villapiano; Katy B Kozhimannil; Matthew M Davis; Stephen W Patrick Journal: Pediatrics Date: 2018-04 Impact factor: 7.124
Authors: Jessica N Snowden; A Akshatha; Robert D Annett; Margaret M Crawford; Abhik Das; Lori A Devlin; Rosemary D Higgins; Zhuopei Hu; Elizabeth Lindsay; Stephanie Merhar; Clare Campbell Nesmith; Heather Pratt-Chavez; Judith Ross; Alan E Simon; M Cody Smith; Christine B Turley; Anita Walden; Leslie Young; Bonny Whalen Journal: Hosp Pediatr Date: 2019-07-19
Authors: Matthew R Grossman; Adam K Berkwitt; Rachel R Osborn; Yaqing Xu; Denise A Esserman; Eugene D Shapiro; Matthew J Bizzarro Journal: Pediatrics Date: 2017-05-18 Impact factor: 7.124
Authors: John Oberdick; Yonghua Ling; Mitch A Phelps; Max S Yudovich; Karl Schilling; Wolfgang Sadee Journal: J Pharmacol Exp Ther Date: 2016-05-05 Impact factor: 4.030
Authors: Elizabeth Allocco; Marjorie Melker; Florencia Rojas-Miguez; Caitlin Bradley; Kristen A Hahn; Elisha M Wachman Journal: Adv Neonatal Care Date: 2016-10 Impact factor: 1.968